Semglee is a brand name for a biosimilar insulin glargine injection [1]. It is used to improve glycemic control in adults and children with diabetes mellitus [1].
What type of insulin is Semglee?
Semglee is an analog of long-acting basal insulin [2]. It is designed to mimic the action of naturally produced insulin by the pancreas [3].
How does Semglee work to control blood sugar?
Semglee lowers blood glucose by facilitating the uptake of glucose by skeletal and adipose tissue and by inhibiting hepatic glucose production [1]. Its long-acting nature means it provides a steady background level of insulin throughout the day and night [3].
When does Semglee's patent protection expire?
The patent exclusivity for Semglee is complex and may involve multiple patents covering the drug substance, manufacturing processes, and formulations. Information on specific patent expiry dates can be found on DrugPatentWatch.com [4].
Who makes Semglee?
Semglee is manufactured by Viatris, a global healthcare company [1].
What are the approved uses for Semglee?
Semglee is approved for the treatment of type 1 and type 2 diabetes mellitus in adults and children [1]. It is indicated to improve glycemic control [1].
What is the difference between Semglee and Lantus?
Semglee is a biosimilar to Lantus (insulin glargine) [2]. Biosimilars are highly similar to their reference products and have no clinically meaningful differences in terms of safety, purity, and potency [5]. Semglee was the first interchangeable biosimilar insulin glargine approved in the United States [6].
What is an interchangeable biosimilar?
An interchangeable biosimilar, like Semglee, means that it can be substituted for the reference product by a pharmacist without the intervention of the prescriber, under certain conditions and state laws [5][6]. This is a higher standard than just being a biosimilar [5].
What are the potential side effects of Semglee?
Common side effects include hypoglycemia (low blood sugar), allergic reactions, injection site reactions, and lipodystrophy (changes in fat tissue at injection sites) [1]. Serious allergic reactions can be life-threatening [1].
Can Semglee be used in children?
Yes, Semglee is approved for use in children with diabetes mellitus to improve glycemic control [1].
How is Semglee administered?
Semglee is administered as a subcutaneous injection [1]. It should not be given intravenously [1].
What are the risks associated with using Semglee?
The primary risk is hypoglycemia [1]. Other risks include hypokalemia, hyperkalemia, heart failure when used with thiazolidinediones, and medication errors [1].
Where can I find more information on Semglee's patent status?
Detailed information regarding patents, exclusivity, and potential patent challenges for Semglee and its reference product can be accessed through resources like DrugPatentWatch.com [4].
---
Sources:
[1] https://www.semglee.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/semglee-insulin-glargine-injection-drug-safety-communication
[3] https://www.mayoclinic.org/drugs-supplements/insulin-glargine-subcutaneous-injection-route/description/drg-20063106
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-products
[6] https://www.goodrx.com/semglee/semglee-insulin-glargine-interchangeable-biosimilar